Inpharmatica Announces Biopendium(TM) Subscription Agreement With Riken of Japan

Inpharmatica's second major deal in Japan with world's

largest structural genomics research centre



Jul 17, 2003, 01:00 ET from Inpharmatica Ltd

    LONDON, July 17 /PRNewswire/ -- Inpharmatica Ltd, a leading
 informatics-driven drug discovery company today announced that Riken of Japan,
 the world's largest structural genomics research centre, has taken a
 non-exclusive subscription to Biopendium(TM), the world's premier proteome
 annotation resource. Financial terms of the agreement were not disclosed.
     Inpharmatica secured this agreement in conjunction with its Japanese
 partner PharmaDesign, which is based in Tokyo. PharmaDesign will provide Riken
 with primary training and support over the period of the subscription.
     Commenting on the announcement, Dr Mark Swindells, Chief Scientific
 Officer at Inpharmatica, said:
     "We are delighted to announce this agreement with Riken, which further
 strengthens our presence within the important Japanese market place. By
 prioritizing proteins using Biopendium(TM), Riken will benefit from
 consistently high quality annotation at a scale that compliments their already
 impressive capabilities in X-ray and NMR determination techniques."
     Professor Yokoyama, Director of the Riken initiative, further commented:
     "It is very important to select the most scientifically interesting
 protein targets for structural and functional determination. We don't want to
 waste time determining structures that turn out to have limited value.
 Inpharmatica's Biopendium(TM) is the best resource of its kind in this field
 and will be a valuable tool in achieving this objective since it is capable of
 providing quality annotation over more of the proteome than any other
 commercially available resource. We are very pleased to have concluded a
 license to this technology."
 
 

SOURCE Inpharmatica Ltd
    LONDON, July 17 /PRNewswire/ -- Inpharmatica Ltd, a leading
 informatics-driven drug discovery company today announced that Riken of Japan,
 the world's largest structural genomics research centre, has taken a
 non-exclusive subscription to Biopendium(TM), the world's premier proteome
 annotation resource. Financial terms of the agreement were not disclosed.
     Inpharmatica secured this agreement in conjunction with its Japanese
 partner PharmaDesign, which is based in Tokyo. PharmaDesign will provide Riken
 with primary training and support over the period of the subscription.
     Commenting on the announcement, Dr Mark Swindells, Chief Scientific
 Officer at Inpharmatica, said:
     "We are delighted to announce this agreement with Riken, which further
 strengthens our presence within the important Japanese market place. By
 prioritizing proteins using Biopendium(TM), Riken will benefit from
 consistently high quality annotation at a scale that compliments their already
 impressive capabilities in X-ray and NMR determination techniques."
     Professor Yokoyama, Director of the Riken initiative, further commented:
     "It is very important to select the most scientifically interesting
 protein targets for structural and functional determination. We don't want to
 waste time determining structures that turn out to have limited value.
 Inpharmatica's Biopendium(TM) is the best resource of its kind in this field
 and will be a valuable tool in achieving this objective since it is capable of
 providing quality annotation over more of the proteome than any other
 commercially available resource. We are very pleased to have concluded a
 license to this technology."
 
 SOURCE  Inpharmatica Ltd